Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 581-585

  Shimizu, Tadao ^a   Hirano, Akira ^a   Watanabe, Osamu ^a   Kinoshita, J U N ^a   Kimura, Kiyomi ^a   Kamimura, Mari ^a   Domoto, Kaoru ^a   Kim, Naomi ^a   Ogawa, Kenji ^a   Fujibayashi, Mariko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Inflammatory breast cancer; Pathological complete response; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; ECHOMAMMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY BREAST CANCER; LEUKOPENIA; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77950534293     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Iwata H, Toi M, Kuroi K and Nakamura S: Report of a questionnaire survey about inflammatory breast cancer in Japan. Jpn J Breast Cancer 21: 201-205, 2006.
2. Hance KW, Anderson WF, Devesa SS, Young HA and Levine PH: Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the national cancer institute. J Natl cancer Inst 97: 966-975, 2005.
3. Giordano SH and Hortobagyi GN: Inflammatory breast cancer: clinical progress and main problems that must be addressed. Breast Cancer Research 5: 284-288, 2003.
4. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Beast Cancer (version 1. 2009)., pp. 56, http://www.nccn.org/ professionals/physician-gls/PDF/breast.pdf. Accessed March 9, 2009.
5. Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21: 309-318, 1999.
6. Smith IE: New drugs for breast cancer. Lancet 360: 790-792, 2002.
7. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
8. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
10. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D and Hortobagyi GN: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685, 2005.
11. National Cancer Institute, Common Terminology Criterion for Adverse Events (version 3.0. 2006)., pp. 19-28, http://ctep.info.ndh.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed March 9, 2009.
12. Green FL, Page DL, Fleming JD, Frittz AG, Balch CM, Haller DG and Morrow M: Breast. In: AJCC Cancer Staging Manual. 6th ed. New York, Springer-Verlag, pp. 255-281, 2002.
13. Dellapasqua S, Colleoni M, Castigione M and Goldhirsch A: New critera for selecting elderly patients for breast cancer adjuvant treatment studies. Oncologist 12: 952-959, 2007.
14. Extermann M, Balducci L and Lyman GH: What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 18: 1709-1717, 2000.
15. Giordano SH, Hortobagyi GN, Kau SC, Theriault RL and Bondy ML: Breast cancer treatment guidelines in older women. J Clin Oncol 23: 1709-1717, 2005.
16. Harris EE, Schultz D, Bertsch H, Fox K, Glick J and Solin L: Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiation Oncology Biol Phys 55: 1200-1208, 2003.
17. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes LR, Koelin CM, Parker LM, Ellisen LW, Kuter I, Godd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL and Winer EP: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21: 46-53, 2003.
18. Asakura H, Takashima H, Mitani M, Haba R, Seo R, Yokoe K, Toyama Y and Ohkawa M: Unknown primary carcinoma, diagnosed as inflammatory breast cancer, and successfully treated with trastuzumab and vinorelbine. Int J Clin Oncol 10: 285-288, 2005.
19. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV and Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
20. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999.